About seller
Alzheimer's disease (AD) is a neurodegenerative disease mainly associated with aging, oxidative stress and genetic mutations. There are two pathological proteins involved in AD; Amyloid-β peptide and microtubule-associated protein Tau (MAPT). Alisertib molecular weight The β- and γ-secretase enzyme cleaves the Amyloid precursor protein, which results in the formation of extracellular plaques in brain. While, Tau undergoes hyperphosphorylation and other post-translational modifications (PTMs), which eventually generates Tau oligomers, and intracellular neurofibrillary tangles (NFTs) in neurons. Moreover, the brain-resident glia and infiltrated macrophages elevate the level of CNS inflammation, which trigger the oxidative damage of neuronal circuits by reactive oxygen species (ROS) and Nitric oxide (NO). Microglia is the primary immune cell in the CNS, which is continuously surveilling the neuronal synapses and pathogen invasion. Microglia in the resting state is called 'Ramified', which possess long surveilling extensions with a small cat me' signals to microglia to either migrate or phagocytose cellular debris. Further, the actin cytoskeleton helps microglia to mediate directed chemotaxis and neuronal repair during neurodegeneration. Hence, we aim to emphasize the connection between purinergic signaling and actin-driven mechanical movements of microglia for migration and inflammation in AD.The potential Aflatoxin B1 (AFB1) binding Lactobacillus fermentum (LC5/a) was used for in vivo AFB1 binding and detoxification in presence of chlorophyll (CL) in male Swiss albino mice. Mice were randomly divided into seven groups. The control groups (CL, AFB1 and LC5/a) received chlorophyll (250 μg/kg b.w), AFB1 (100 μg/kg b.w) and LC5/a (1 × 108 CFU) for 21 days. The treatment group (AFB1+LC5/a) received 100 μl of lyophilized bacterial suspension (1 × 108 CFU) 2 h before the AFB1 dosage (100μg/kg b.w). The chlorophyll mice group (CL + AFB1) was given single oral dose of CL (250 μg/kg b.w) before AFB1 dosage and last mice group received the combination of CL + LC5/a before the AFB1 dosage over a period of 21 days. Ballooning of cytoplasm and necrosis in liver was evident in histopathological examination of AFB1 mice group, while, marked improvement and nearly normal histology were seen in LC5/a and CL treated mice group. The levels of AST, ALT, GST, and SOD were increased in AFB1 mice group compared to LC5/a and CL treated mice group. Elevated levels of pro-inflammatory cytokines, TNF-α, IL-12, IL-6 (324, 506, 117.25 pg/ml) were observed in AFB1 treated mice serum compared to LC5/a and CL treated mice (249.54, 322.01 and 82.35 pg/ml). Thus, Lactobacillus fermentum LC5/a has certainly sequestered AFB1 from gastrointestinal tract besides regulating the production of pro-inflammatory cytokines.In this study, 6-(6-aminohexyl) amino-6-deoxy-β-cyclodextrin-gellan gum complex hydrogel (HCD-GG) was developed to enhance the affinity of anti-inflammatory drug dexamethasone (Dx), improve chondrogenesis, and decrease the inflammatory response. The modified chemical structure was confirmed by NMR and FTIR. Mechanical and physicochemical properties were characterized by performing viscosity study, compression test, injection force test, swelling kinetic, weight loss, and morphological study. The release profile of the drug-loaded hydrogels was analyzed to confirm the affinity of the hydrophobic drugs and the matrix and characterize cumulative release. In vitro test was carried out with MTT assay, live/dead staining, glycosaminoglycan (GAGs) content, double-stranded DNA (dsDNA) content, morphological analysis, histology, and gene expression. In vivo experiment was conducted by implanting the samples under a subcutaneous area of SPD rat and cartilage defected rabbit model. The results displayed successfully synhave the potential for cartilage regeneration along with multiple applications in tissue engineering and regenerative medicine.As a result of its ability to target certain drugs and/or peptides to the colonic region for the treatment of several diseases while avoiding systemic absorption and potential side effects, colon drug delivery has become a field of research of growing interest. Developing new pharmaceutical formulations capable of reaching the colon requires a broad knowledge of natural and synthetic/semisynthetic polymers. Chitosan, polyethylene-oxide, hydroxypropyl methylcellulose, pectin, natural gums, alginates and polymethacrylates have shown promise when applied in the development of colon drug delivery systems, which range from classic formulation strategies such as tablets and capsules to more sophisticated approaches like nanosystems and integrated osmotic-like formulations. This work aims to bring together knowledge regarding the materials and processes used in the development of such pharmaceutical formulations, as well as to highlight recent advances in the field.Alzheimer Disease (AD) is a neurodegenerative disease characterized by two neuropathological hallmarks extracellular deposition of amyloid plaques and intracellular neurofibrillary tangles. Current treatment for AD (donepezil, galantamine, rivastigmine and memantine) is only symptomatic and has modest benefits. Thus, the development of drugs with the potential to change the progression of the disease has been a priority. Therapies targeting amyloid β have been the focus for almost 30 years. However, highly promising drugs recently failed to show clinical benefits in phase III trials. Even the positive findings presented by Biogen on Aducanumab are not entirely clear and further data is necessary to confirm its validity. Therefore, researchers are turning their efforts around to tau-targeting therapies, since tau protein appears to be better correlated with the severity of cognitive decline than amyloid β. Currently, most anti-tau agents in clinical trials are immunotherapies and they are in the early stages of clinical research. Four monoclonal antibodies anti-tau (Gosuranemab, Tilavonemab, Semorinemab and Zagotenemab) and one anti-tau vaccine (AADvac1) have reached phase II, so far. In this review, we discuss the potential disease-modifying agents tested in clinical trials and update the information of drugs that are still under clinical evaluation.